SmithKline/Miles
This article was originally published in The Tan Sheet
Executive Summary
SmithKline completes sale of Sterling Winthrop's North American OTC business to Bayer AG's U.S. subsidiary Miles for $1 bil. in cash, the firms reported Nov. 3. On Nov. 2, SmithKline announced the completion of its purchase of Sterling's worldwide nonprescription business for $2.9 bil. in cash. SmithKline retains North American and worldwide rights to analgesic Panadol and Canadian rights to antacid Gaviscon, while divesting its rights to Phillips' Milk of Magnesia in Mexico. SmithKline declared that the sale of the Sterling North American business "completes the most significant series of transactions ever made in the OTC industry" ("The Tan Sheet" Sept. 19, p. 1)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning